We examined KIT and NTRK1 gene expression using the publicly available R2: Genomics analysis and visualization platform (http://r2.amc.nl) in patients with cancers of neurological [NB, glioma, pheochromocytoma (PCC), and paraganglioma (PGL)] or hematological origins (AML, ALL, CLL, lymphoma, and myeloma). The gene discussed is KIT; the disease is central nervous system cancer.